Amylyx Pharmaceuticals

Amylyx makes medicines for people with rare brain and hormone issues. These treatments help patients with low blood sugar or nerve diseases. The company finds solutions for families with few medical options.

Seeking Answers for Rare Diseases

• Avexitide: Glucagon-like peptide-1 (GLP-1) receptor antagonist designed to prevent dangerously low blood sugar levels in patients who have had weight-loss surgery; this hormone-blocking drug is currently in Phase 3 testing for post-bariatric hypoglycemia (PBH).
• AMX0035: Investigational combination of two compounds intended to treat Wolfram syndrome, which is a rare genetic condition that causes vision loss, hearing loss, and diabetes.
• AMX0114: Early-stage treatment using antisense oligonucleotide (ASO) technology, a type of genetic-based medicine, to target proteins that cause nerve damage in patients with amyotrophic lateral sclerosis (ALS).
• AMX0318: Long-acting candidate identified through research partnerships for treating rare endocrine and metabolic disorders; currently undergoing studies to enable human clinical trials.

Strategic Moves and Milestones

• Acquired a significant patent portfolio for avexitide from Eiger Pharmaceuticals, Inc. in July 2024 to strengthen its clinical pipeline in endocrine diseases.
• Partnered with Gubra A/S to identify and develop AMX0318 using specialized peptide-based drug discovery methods.
• Collaborated with Breakthrough T1D to provide drug supplies for external research investigating AMX0035 as a treatment for insulin resistance in type 1 diabetes.
• Advanced the HELIOS clinical trial for AMX0035, reporting positive data for pancreatic function in adults living with Wolfram syndrome throughout 2024 and 2025.

A Precise Scientific Approach

Amylyx targets specific biological pathways, such as endoplasmic reticulum (ER) stress and mitochondrial dysfunction, which are linked to cell death in various rare diseases. The company uses a contract-based manufacturing model to produce its investigational drugs rather than operating its own production facilities.

Financial Facts for 2025

• Net loss was $33 million in Q4 2025, which narrowed 12.1% from the previous year.
• Free cash flow hit -$28 million in Q4 2025, an improvement of 52.6% over Q4 2024.
• Operating income reached -$36.6 million in Q4 2025, which improved by 10% year-over-year.
• Market capitalization was $1.1 billion in Q4 2025, representing a 340.6% increase from Q4 2024.
• Revenue was $0 in Q4 2025, compared to a negative $665,000 in Q4 2024.

Bottom Line

Amylyx has transitioned into a clinical-stage developer focused on endocrine and neurological conditions. Its pipeline of mid-to-late-stage candidates serves as the primary driver for future growth and patient impact.